[Public Notice+] Cellivery Successfully Registers US Patent for Anticancer Drug 'iCP-SOCS3'

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 31st that its anticancer drug candidate iCP-SOCS3 has successfully been registered as a patent in the United States.

The anticancer drug iCP-SOCS3 developed by Cellivery has demonstrated excellent anticancer efficacy in liver cancer, pancreatic cancer, lung cancer, and various solid tumors (breast cancer, colorectal cancer, stomach cancer, brain tumors, etc.) as well as tumor angiogenesis inhibition. Separate patents for five indications have been filed in the United States and Europe (EU). According to the company, this U.S. patent is a new and progressive patent registered independently in the U.S. for pancreatic cancer treatment, following the previous patent for liver cancer indication (U.S. 10385103).

Daewoong Cho, CEO of Cellivery, said, "iCP-SOCS3 has received its second U.S. patent registration for pancreatic cancer following liver cancer," adding, "Additional patent applications for three indications including lung cancer, various solid tumors, and tumor angiogenesis inhibition have been independently filed, so we expect continuous patent registrations in the U.S. and the European Union."

He stated, "Successfully registering the patent for iCP-SOCS3’s primary indication as a pancreatic cancer treatment drug is expected to positively influence ongoing licensing-out (L/O) negotiations with a Chinese pharmaceutical company," emphasizing, "We will challenge licensing-out for individual cancer types to global pharmaceutical companies." He further added, "L/O essentially means selling patent rights, and securing patent rights means securing the product to sell. For a biotech company developing new drugs and using L/O of these substances as a business model, obtaining patent rights in major countries is of absolute value to the business."

The iCP-SOCS3, which applies the pharmacological substance in vivo delivery technology TSDT platform technology, is rapidly delivered to the pancreas where cancer cells exist. Mechanism-specifically, it inhibits the growth and induces apoptosis of pancreatic cancer cells. On the other hand, it does not affect normal cells at all, thus overcoming the side effects of conventional anticancer drugs. The company stated that in a pancreatic cancer animal model, a comparative test of anticancer efficacy between the existing standard pancreatic cancer treatment drug Gemzar (Eli Lilly) and iCP-SOCS3 showed that while Gemzar demonstrated 77% anticancer efficacy, iCP-SOCS3 showed 98% efficacy, proving its excellence as a new drug.

CEO Cho emphasized, "Currently, Cellivery is jointly conducting research on antibody therapeutics targeting pancreatic cancer cell inducers with a U.S.-based global top 3 pharmaceutical company. Although the exact timing is unknown, we expect results within the first half of the year and are doing our best."

Pancreatic cancer is known to have the lowest cure rate among cancers, with a 5-year survival rate of about 7.6% after surgery. Because it shows almost no symptoms in the early stages and is located deep inside the body surrounded by other organs, it cannot be felt from the outside, making early diagnosis very difficult. For this reason, most cases are discovered after the cancer has progressed, and less than 20% of these cases are operable by surgery, making the development of anticancer drug treatments urgently needed for this cancer type.

This content was produced with the assistance of AI translation services.